期刊文献+

唑来膦酸联合放射治疗42例骨转移性癌的临床观察 被引量:2

Effect of the combination of zoledronic acid and radiotherapy on treatment of patients with bone metastasis
下载PDF
导出
摘要 目的观察唑来膦酸联合放射治疗骨转移性癌的疗效及毒副作用。方法 42例确诊的骨转移性癌随机分为治疗组22例(放疗+唑来膦酸)和对照组20例(单纯的放疗)。观察治疗前后疼痛的缓解、活动能力改善及副作用。结果治疗结束时两组疼痛缓解率没有统计学差异(86.4%vs 80%,P>0.05),但治疗结束后3月开始,两组疼痛缓解率有统计学差异(81%vs 50%,P<0.05)。结论唑来膦酸联合放射治疗骨转移性癌的疗效优于单纯放疗,疼痛缓解持续时间更长,毒副作用能耐受。 Objective To observe the efficacy and adverse effect of the combination of zoledronic acid and radiotherapy in treatment of patients with bone metastasis.Methods 42 histological and cytological confirmed bone metastasis patients were randomly assigned to therapeutic group and control group,which were treated with zoledronic acid combined with radiotherapy and radiotherapy alone,respectively.Results There were no significant difference between the two groups for reducing the pain at the finish time of treatment(86.4% vs 80%,P〈0.05).However,there were significant differences for reducing pain and ECOG PS improving between the two groups 3 months after treatment(81% vs 50%,P〉0.05).Conclusion The combination of zoledronic acid with radiotherapy was superior radiotherapy alone for patients with bone metastasis and the release time was longer,the adverse effects were tolerable.
出处 《西部医学》 2010年第7期1224-1226,共3页 Medical Journal of West China
关键词 唑来膦酸 放射治疗 骨转移性癌 Zoledronic acid Radiotherapy Bone metastasis
  • 相关文献

参考文献16

  • 1Woodhouse EC , Chuaqui RF , Liotta LA. General mechanismsof metastasis[J]. Cancer , 1997 , 80 (8 Suppl) : 1529.
  • 2Fuller K, Wong B, Fox S, et al. TRANCE isneeessary and sufficient for osteoblast-mediatedactivation of bone resorption in osteoclasts[J]. J Exp Med 188 : 997-1001, 1998.
  • 3Lacey DL, Tan HL, Lu J, et a. Osteoprotegerin ligand modulates murlne osteoclast survival in vitroand in vivo[J]. Am J Pathol 157:435-448, 2000.
  • 4Lacey DL, Timms E, Tan HL, eta. : Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation [J]. Cell 93:165-176, 1998.
  • 5Brown JE, Cook RJ, Major P, et al. Boneturnover markers as predictors of skeletal complicationsin prostate cancer, lung cancer, and other solidtumors[J]. J Natl Cancer Inst 97: 59-69, 2005.
  • 6Brown JE, Thomson CS, Ellis SP, et al. Bone resorption predicts for skeletal complications in metastatic bone disease[J]. Br J Cancer 89:2031-2037,2003.
  • 7Costa L, Demers LM, Gouveia-Oliveira A, et al. Prospective evaluation of the peptide-bound collagentype Ⅰ cross-links N-telopeptide and C-telopeptide in predicting bone metastases status [J]. J Clin Oncol 20:850-856, 2002.
  • 8Green JR, Mu¨ ller K, Jaeggi KA: Preclinical pharmacology of CGP 42_446, a new, potent, heterocyelic bisphosphonate compound[J]. J BoneMiner Res 9:745-751, 1994.
  • 9Maxwell C, Swift R, Noonan K: Convenienceof a 15-minute infusion of zoledronic acid. Presented at: Presented at the 3rd European Oncology Nursing Symposium Spring Convention[J]. Venice, Italy, April 12-14, 2002.
  • 10Major P, Lortholary A, Hon J, et al. Zoledronic acid is superior to pamidronate in thetreatment of hypercalcemia of malignancy: A pooled analysis of two randomized, controlledclinical trials [J]. J Clin Oncol 19:558-567, 2001.

同被引文献63

引证文献2

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部